Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review

Aoife Rodgers, Emilie Kruke Indreberg, Lenah Alfallaj, Manasi Nadkarni, Zubair Kabir*

*School of Public Health, University College Cork, Cork, Ireland.

Corresponding Author: Dr Zubair Kabir (email: z.kabir@ucc.ie)

Abstract

Background: The novelty of the Covid-19 pandemic is reflected in the lack of literature available for the impact of smoking on the intensity of the COVID-19 clinical manifestations. Our study tries to address this gap.

Method: Six cohorts from China were analysed and a crude odds ratio was manually calculated.

Results: Patients with a smoking history were approximately 2 times (95% CI= 1.036-1.883) as likely to suffer from severe clinical manifestations of COVID-19 compared to patients without a smoking history. A higher percentage of males suffer more severe symptoms of COVID-19 in comparison to females, but this could be associated with the gender specific smoking trends observed in China.

Conclusion: The gender specific smoking trends could be associated with the increased severity of COVID-19 disease manifestations in the male population.

Ethical Considerations: No personal data were used, therefore no ethical approval was sought

Conflicts of Interest: No conflicts of interest

Funding: No funding was available to this study. This was a part of Master of Public Health (MPH) student project.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

BACKGROUND

Coronavirus, belonging to the Coronaviridae family, has been previously seen before and is known to cause a human illness with symptoms similar to the common cold (1). Coronavirus has been shown to be a zoonotic disease in nature, and in the case of COVID-19 originating from bats (2). In the last decade, this is the third deadliest coronavirus pandemic (2). In 2003, there was an outbreak of coronavirus known as Severe Acute Respiratory Syndrome (SARS) and in 2012 another strain of coronavirus known as Middle-East Respiratory Syndrome (MERS) emerged (3,4). A more recent strain of coronavirus has emerged named SARS-COV-2 and is generally referred to as COVID-19 (Coronavirus disease 2019). COVID-19 began in Wuhan, China in December 2019 (5). Within a month of its appearance, the World Health Organization had declared COVID-19 as a global pandemic (5). To date, there have been 3,110,696 declared cases with 215,231 deaths (6) and within the past 5 months, over 100 countries have been infected with COVID-19 (7). Due to the novelty of COVID-19, there is limited data available on the characteristics associated with COVID-19 (5).

Most human Coronaviruses cause mild symptoms. However, a subgroup of coronaviruses is causing severe outcomes. Severe Acute Respiratory Syndrome (SARS) and Middle-East Respiratory Syndrome (MERS) have a death rate of 10% and 37% respectively (8). The mortality rate for COVID-19 is almost 7% based on the current numbers (6). Shortness of breath (9), fever and cough are the main symptoms for the three coronaviruses, including COVID-19, leading to a lower

respiratory infection that can be life-threatening to vulnerable groups such as to the elderly and to people with underlying medical conditions (10,11). This leads to respiratory failure and multiorgan failure (12). Cases of COVID-19 are divided into four groups mild, moderate, severe and critical pneumonia (11).

To date, there is limited data on the role smoking has to play in the progression of COVID-19, however, smoking has been identified as a risk factor for disease progression (5,13). A previous meta-analysis involving thirteen studies was carried out and determined smoking to be a risk factor in disease progression for patients with COVID-19 (13). Similarly, in the previous MERS outbreak, smokers were identified as having a higher mortality rate in comparison to non-smokers (5). In more recent literature, a systematic review of five papers in China found that smokers were 1.4 times more likely to have more severe symptoms of COVID-19 and 2.4 times more likely to be admitted to an ICU, need mechanical ventilation or died in comparison to non-smokers (RR = 2.4, 95% CI: 1.43-4.04) (5).

According to another meta-analysis that is done on 39 studies, males had more severe outcomes in comparison to females, as well as the mortality rate (11). It is not fully understood yet, however, it can be explained with the presence of estrogen is a protective factor. Also, it is linked that smoking is considered a risk factor for adverse outcome and the number of men smoking is higher than women.

Smoking prevalence can vary by country to country however in general, the smoking prevalence is higher among males than females (14),(15). It has been highlighted

that developing countries and developed countries are similar in their male smoking mean (32% and 30.1% respectively) however, females in developed countries have a higher prevalence of smoking in comparison to females in developing countries (17.2% vs. 3.1%) (14). The World Health Organization's Global Adult Tobacco Survey 2018 supports the statement males have a higher prevalence of smoking compared to females (15.6% vs 12.0%) globally (15). Due to these trends observed in the smoking difference between genders, it could lead to an indirect association between the severity of COVID-19 between genders.

RESEARCH QUESTION

Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke?

Table 1: Question in PICO format

Population	All COVID-19 cases
Intervention	Male smokers
Comparison	Female smokers
Outcome	Severe symptoms of COVID-19

METHODOLOGY

Search strategy and Selection criteria

A search was conducted in the PubMed database for studies published between January 1, 2020, to April 27, 2020. The Zotero 5.0.85 software was used to manage the selected studies. A comprehensive search was designed for the purpose of this study (Appendix 1). No language restrictions were placed on this search. Only full-text studies were included in the

evidence synthesis. The studies identified by this search were further analysed for their eligibility. Eligible studies were those that demonstrated the characteristics presented in Table 2. The flow for the number of studies included in the evidence synthesis is given in Figure 1.

Table 2: The inclusion and exclusion criteria used in the report.

Inclusion

- Cross-sectional studies, surveys, cohort studies or case studies conducted in China
- Studies that described the epidemiological and/or clinical characteristics of the coronavirus infection
- Studies that described the prevalence of smoking in the sample population, either as a whole or based on gender

Exclusion

- Preprints, reviews, editorials and letters
- Studies that provided no data about the smoking status of the sample populations affected by the coronavirus infections
- Studies with less than 100 participants

Figure 1: Flowchart for selecting the studies included in the evidence synthesis

Synthesis of evidence

The final number of included studies to synthesise for evidence was six (16,17,18,19,20,21). The six studies were mined for the following components: the total number of cases, the number of cases in males versus females, the gender stratified severity of the cases and the history of smoking (Table 3). The severe cases were those listed as severe cases, on mechanical ventilation or had died from the virus in each paper. Each study was also analysed to determine its quality. The quality of the included studies was assessed using the “Newcastle-Ottawa Quality Assessment Form for Cohort Studies”. Depending on the number of stars in each

of the three domains (selection, comparability and outcome) the quality was considered good, fair or poor (22). Overall the quality for each study was considered good with low risk of bias (Appendix 4).

Analysis

The data extracted from the studies (Table 3) was used to manually calculate a Crude Odds Ratio (COR) (Appendix 2). The mean COR was calculated as an overall estimate of the risk of severe clinical manifestations for patients with a history of smoking. The 95% Confidence Interval (95% C.I.) was estimated using the online OpenEpi tool Version 3.01.

RESULTS

Table 3: Overview of the six studies included in the review

Study, design and year	Year and Setting	Cases	Male	Female	Male severe	Female severe	History of smoking	Smokers Severe	Quality	OR (95% CI)
Zhou et al. Cohort 2020	Jinyintan hospital, Wuhan Pulmonary Hospital Wuhan, China	191	199	72	38	16	11	5	Good	2.23 (0.65-7.63)
Guan et al. Cohort 2020	552 Hospitals in China	1096	637	459	100	73	158	38	Good	1.88 (1.25-2.83)
Mo et al. Cohort 2020	Zhongnan Hospital of Wuhan University, China	155	86	69	55	30	6	4	Good	1.51 (0.27-8.48)
Shi et al. Cohort 2020	Hospitals in Zhejiang, Province of China	487	259	228	36	13	40	6	Good	1.66 (0.66-4.17)
Zhang et al. Cohort 2020	7 Hospitals in Wuhan, China	140	71	69	33	25	9	6	Good	3.04 (0.73-12.69)
Chen et al. Cohort 2020	Tongji Hospital Wuhan, China	274	171	103	83	30	16	9	Good	1.9 (0.69-5.27)
Total		2343	1343	1000	345	187	240	68		1.92 (1.04-1.88)

OR (odds ratio), CI (confidence interval)

DISCUSSION

Due to the novelty of COVID-19, there is a lack of evidence on the impact of gender-stratified smoking on disease progression. In order to elucidate the presence of this association, this paper analyzed six specific cohort studies within China to synthesize the relevant evidence. The rationale for papers only chosen within China is due to COVID-19 originating in China. China in turn, has an extensive amount of research completed on COVID-19 in comparison to any other countries worldwide. The analysis was carried out to identify whether gender differences in smoking have an effect on the severity of the symptoms on the current coronavirus strain, COVID-19, by gathering data and calculating the odds ratios for the selected cohorts. The analysis of the data extracted from these studies indicated that patients with a smoking history were approximately 2 times (OR=1.92; 95% CI= 1.036-1.883) as likely to suffer from severe clinical manifestations of COVID-19 compared to patients without a smoking history. However, there was a lack of evidence available on the differences in gender and their smoking rates. From the six cohorts in China, the smoking data for a total of 1343 males and 1000 females was analyzed. A higher proportion of males suffer from more severe symptoms of COVID-19 within China, as observed in the six cohorts where 158 more males suffered from severe cases (25%) in comparison to severe female cases (18.7%). Simultaneously, it was observed that males had a higher prevalence of smoking in comparison to females both within China (54% male smokers and 2.6% female smokers) (23). This observation supports our hypothesis that a higher proportion of men suffer from

severe manifestations, as compared to females, due to the higher prevalence of smoking amongst men in China. Similarly, other countries badly affected by COVID-19, such as Italy have found that males (22.8%) are more likely to smoke in comparison to females (14.9%) (24).

Furthermore, it was observed that within the Italian population, 58% of the COVID-19 cases were male cases (25). However, in the cohort studied in Italy (Appendix 3), it was observed that patients with a smoking history were 0.35 times less likely to exhibit severe symptoms of Covid-19 than those that had no smoking history (26). Considering the fact that this is the only cohort outside China, this could indicate that further studies are needed to identify whether there are any confounders that could impact this potential association.

Previous strains of coronavirus outbreaks such as SARS outbreak in 2003 and MERS outbreak in 2012, determined a significantly higher death rate among males (21.9% vs 13.2%). The receptor used by the previous SARS-CoV viral strain to enter the host cells is the angiotensin-converting enzyme-2 (ACE2) receptor (27). It has been hypothesized that this receptor could be used as the novel adhesion molecule by the current SARS-CoV2 (COVID-19) strain. Smoking has been associated with the upregulation of this receptor molecule, thus increasing the susceptibility to more severe clinical manifestation of the disease. The use of new electronic smoking devices such as electronic cigarettes has also been hypothetically associated with this upregulation (27). This receptor upregulation and gender difference in smoking rates could help explain the higher proportion of severe cases observed in

males as opposed to females, in several countries.

A similar gender-specific smoking pattern was observed in Ireland, where a study carried out by the Health Service Executive (HSE) Healthy Ireland found 24% of the male population to be smokers as opposed to 21% observed in the female population (28). Thus, indicating that Irish males are more vulnerable to severe COVID-19 cases than Irish females. As observed in Italy, a cohort study could demonstrate a negative association between smoking and severity of Covid-19 (26). This indicates that further research is necessary before any association is determined in Ireland. However, while there are no studies to support the evidence, data published by the Health Protection Surveillance Centre, states that although males account for only 46% of confirmed cases, they account for 71% of deaths, which is a severe outcome (29). This observation has an essential public health implication, as it could be used as the driving force for an amendment in the existing Irish Smoking Ban. In 2004, Ireland imposed a blanket ban on smoking in enclosed public spaces as well as workplaces. But this ban did not extend to open public spaces, such as parks, beaches, playgrounds, and campuses, or include the use of electronic cigarettes (30). In order to reduce the smoking associated gender specific disease burden, amending the current smoking ban to restrict smoking in open public places and ban the use of e-cigarettes might be necessary to reduce the incidence of severe cases of COVID-19 in the Irish population, thus decreasing the burden on the healthcare services. This amendment could also aid in achieving the 2025 targets of less than 5% smoking prevalence in Ireland (28).

LIMITATIONS

The novelty of the Covid-19 pandemic is reflected in the lack of literature available for the impact of smoking on the intensity of the COVID-19 clinical manifestations. While our study tries to bridge this gap, it also possesses certain limitations. A meta-analysis could not be performed due to the lack of studies that matched the inclusion criteria, as less than 10 papers were selected for this review. The methods used to collect data related to smoking history varied across the studies, thus introducing heterogeneity, and, in cases of self-reported data, recall bias. While the selected papers provided gender-stratified data for the severity of cases, they did not provide the gender-stratified data for smoking. Therefore, the studies had to be supported by the gender specific smoking trends observed in the population of China to elucidate the association observed in this review. Furthermore, there was no data collected to determine whether the smoking history was recent. Thus, a concrete cause-effect relationship could not be determined on the basis of the available data.

CONCLUSION

The analysis of the data extracted from six cohorts in China, as well as the supplementary data regarding the gender differences in smoking, indicated that smoking could be associated with the increased severity of COVID-19 disease manifestations in the male population, in comparison to the female population. Due to the similarity in smoking trends observed in other countries such as Italy and Ireland, this gender specific smoking associated distribution of severe COVID-19 cases might also be observed in these

populations. Thus, an amendment in the Irish Smoking Ban, which restricts smoking in open public places such as parks, beaches, playgrounds, and campuses and a ban on the use of e-cigarettes, may help curb the incidence of severe cases of COVID-19 in the Irish population, thus decreasing the burden on the healthcare services. However, the lack of concrete gender-specific smoking data within the cohort studies suggests that further research is necessary to verify this hypothesis.

REFERENCES

1. National Center for Immunization and Respiratory Diseases. Common Human Coronaviruses. Centers for Disease Control and Prevention. 2020 Feb 13;1.
2. Al-Qahtani AA. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi Journal of Biological Sciences. 2020 Apr;S1319562X20301558.
3. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019 Dec;16(1):69.
4. National Center for Immunization and Respiratory Diseases. About Middle East Respiratory Syndrome (MERS) [Internet]. Centers for Disease Control and Prevention. 2019 [cited 2020 May 7]. Available from: <https://www.cdc.gov/coronavirus/mers/about/index.html>
5. Vardavas C, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis [Internet]. 2020 Mar 20 [cited 2020 May 7];18(March). Available from:

- <http://www.journalssystem.com/tid/C-OVID-19-and-smoking-A-systematic-review-of-the-evidence,119324,0,2.html>
6. Avi Schiffmann. World COVID-19 Stats [Internet]. ncov2019.live. 2020 [cited 2020 May 7]. Available from: <https://ncov2019.live/data>
7. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? *The Lancet*. 2020 Apr;395(10231):1225–8.
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020 Feb;395(10223):497–506.
9. Vázquez J, Redolar-Ripoll D. COVID-19 outbreak impact in Spain: A role for tobacco smoking? *Tob Induc Dis* [Internet]. 2020 Apr 6 [cited 2020 May 7];18(April). Available from: <http://www.journalssystem.com/tid/C-OVID-19-outbreak-impact-in-Spain-A-role-for-tobacco-smoking-,120005,0,2.html>
10. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020 Apr 7;323(13):1239.
11. Wei X, Xiao Y-T, Wang J, Chen R, Zhang W, Yang Y, et al. Sex Differences in Severity and Mortality Among Patients With COVID-19: Evidence from Pooled Literature Analysis and Insights from Integrated Bioinformatic Analysis. :43.
12. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood*. 2020 Apr 27;blood.2020006000.
13. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *Journal of Infection*. 2020 Apr;S0163445320302346.
14. Chinwong D, Mookmanee N, Chongpornchai J, Chinwong S. A Comparison of Gender Differences in Smoking Behaviors, Intention to Quit, and Nicotine Dependence among Thai University Students. *Mundt MP*, editor. *Journal of Addiction*. 2018 Oct 24;2018:8081670.
15. Office on Smoking and Health. Fast Facts and Fact Sheets: Smoking & Tobacco Use [Internet]. Centers for Disease Control and Prevention. 2019 [cited 2020 May 7]. Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/index.htm
16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020 Mar;395(10229):1054–62.
17. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020 Apr 30;382(18):1708–20.
18. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clinical Infectious Diseases*. 2020 Mar 16;ciaa270.
19. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487

- cases outside Wuhan. *Crit Care*. 2020 Dec;24(1):108.
20. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020 Feb 27;all.14238.
  21. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020 Mar 26;m1091.
  22. Universities of Newcastle, University of Ottawa. Newcastle-Ottawa Quality Assessment Form for Cohort Studies.
  23. Lai Lin Thomala. Share of adult population who smoke in China by gender [Internet]. Statista. 2019 [cited 2020 May 7]. Available from: <https://www.statista.com/statistics/916348/china-share-of-smoking-adults-by-gender/>
  24. Tobacco: Italy [Internet]. The Tobacco Atlas. 2016 [cited 2020 May 7]. Available from: <https://tobaccoatlas.org/country/italy/>
  25. Walter L, McGregor A. Sex- and Gender-specific Observations and Implications for COVID-19. *WestJEM* [Internet]. 2020 Apr 10 [cited 2020 May 7];21(3). Available from: <https://escholarship.org/uc/item/76f9p924>
  26. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thrombosis Research*. 2020 Jul;191:9–14.
  27. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). *JCM*. 2020 Mar 20;9(3):841.
  28. Sheridan A, O'Farrell A, Evans D, Kavanagh P. Adult Smoking in Ireland. Health Service Executive. 2018 May;23.
  29. Ronan McGreevy. Coronavirus: Why are men twice as likely to die as women? [Internet]. THE IRISH TIMES. 2020 [cited 2020 May 12]. Available from: <https://www.irishtimes.com/news/ireland/irish-news/coronavirus-why-are-men-twice-as-likely-to-die-as-women-1.4222408>
  30. Bernd Biege. What You Need to Know About the Irish Smoking Ban [Internet]. TripSavvy. 2019 [cited 2020 May 7]. Available from: <https://www.tripsavvy.com/the-irish-smoking-ban-explained-1542836>

APPENDIX 1

Search term for evidence synthesis

Search Number	Search Term
1	“coronavirus OR COVID-19 OR SARS OR severe acute respiratory syndrome”
2	“smoke OR smoking OR risk factor OR characteristics”
3	“smoke OR smoking OR risk factor OR characteristics” AND “sex OR gender OR men OR male OR women OR female”
4	1 AND 2 AND 3

APPENDIX 2

Crude Odds Ratio (COR)

$COR = (aXd)/(bXc)$

The summarized data in each cell

a	Number of cases that reported a smoking history as well as severe clinical manifestation
b	Number of cases that reported a smoking history but did not report a severe clinical manifestation
c	Number of cases that did not report a smoking history but reported severe clinical manifestation
d	Number of cases that neither reported a smoking history nor any severe clinical manifestation

APPENDIX 3

COVID-19 comparison

Country	Italy
Author, Design and Year	Lodigiani et al. Cohort 2020
Setting	University hospital in Milan, Italy
Total cases	388
Male cases	264
Female cases	124
Severe male cases	49

Severe female cases	12
Total smokers	45
Severe smokers	3
Odds Ratio	0.35

APPENDIX 4

Newcastle-Ottawa Quality Assessment for Cohort Studies

Study	Selection				Comparability	Outcome			Total
	representative	Selecting non-exposed	ascertainment	outcome not present at start	confounders	assessment	long enough follow-up	adequacy of follow-up	
Zhou et al.	*	*	*	*	**	*	*	*	Good
Guan et al.	*	*	*	*	**	*	*	*	Good
Mo et al.	*	*	*	*	*	*	*	*	Good
Shi et al.	*	*	*	*	*	*	*	*	Good
Zhang et al.	*	*	*	*	*	*	*	*	Good
Chen et al.	*	*	*	*	**	*	*	*	Good

A study can be given a maximum of one star for each numbered item within the Selection and Outcome categories.
A maximum of two stars can be given for Comparability.